

Applicants: David Baltimore et al.
Serial No.: CPA of 08/813,323
Filed : March 10, 1997
Page 3

REMARKS

Claims 3, 4 and 92 are pending in the above-identified application. By this Amendment applicants have canceled claims 3, 4 and 92 and added new claims 93 and 94. New claim 93 is supported by the application as originally filed, for example at page 8, lines 3-7; page 12, lines 13-14; Figure 1; and Figure 3, *inter alia*. New claim 94 is supported by the application as originally filed, for example at page 8, lines 3-7; page 12, lines 13-14; Figure 1; and Figure 3, *inter alia*. Applicants maintain that the amendments to the claims raise no issue of new matter and therefore request that the Amendment be entered into the application. After entry of this Amendment claims 93 and 94 will be pending.

In addition, applicants have corrected the Sequence Listing. Applicants inadvertently omitted the carboxy-terminal residue from SEQ ID NO:1 (Figure 1) in the Sequence Listing filed November 25, 1997 with the United States Patent and Trademark Office in connection with the above-identified application. Accordingly, applicants attach hereto a paper copy sequence Listing, a Computer Readable Form Sequence Listing and a Statement in Accordance with 1.821(f) as **Exhibit B**. Applicants maintain that the corrected Sequence Listing raises no issue of new matter.

Rejections Under 35 U.S.C. §112, First Paragraph

The Examiner stated that rejection under 35 U.S.C. §112, first paragraph of claims 3, 4, 92, pertaining to lack of a clear written description of an amino-terminal at amino acid 385, remains for reasons already of record in paper No. 24.

Applicants: David Baltimore et al.
Serial No.: CPA of 08/813,323
Filed : March 10, 1997
Page 4

The Examiner stated that applicants assert that page 8, lines 3-5 of the specification disclose a portion of SEQ ID NO:1, which portion has as its amino-terminal boundary any one of amino acid residues from 324 to 415 of SEQ ID NO:1. The Examiner stated that applicants' arguments set forth in paper No.25 have been considered but are not deemed to be persuasive for the following reasons: page 8, lines 3-5 of the specification does not disclose a portion of SEQ ID NO:1, which portion has as its amino-terminal boundary any one of amino acid residues from 324 to 415 of SEQ ID NO:1. The Examiner stated that page 8, lines 3-5 of the specification only discloses a truncated CRAF1 by from about 323 to about 414 amino acid residues at the amino terminus, or a variant thereof capable of inhibiting CD-40 mediated cell activation.

In response, without conceding the correctness of the Examiner's position, applicants have canceled claims 3, 4, and 92 and added new claims 93 and 94. As noted above, new claims 93 and 94 are fully supported by the specification as originally filed.

Rejection Under 35 U.S.C. §102(b)

The Examiner stated that the rejection under 35 U.S.C. §102(b) of claims 3, 4, 92, pertaining to anticipation by Sato et al., remains for reasons already of record in paper No. 24.

The Examiner stated that applicants assert that the protein disclosed by Sato et al. does not have an amino-terminus between residues 324 and 385 of SEQ ID NO:1, and that the amino-terminus of the Sato protein occurs at residue 387. The Examiner stated that applicants' arguments set forth in paper No. 25 have been

Applicants: David Baltimore et al.
Serial No.: CPA of 08/813,323
Filed : March 10, 1997
Page 5

considered but are not deemed to be persuasive for the following reasons: The Examiner stated that the claims do not necessarily read on a protein having an amino-terminus between residues 324 and 385 of SEQ ID NO: 1, and, thus, applicants argue a limitation not in the claims.

In response, without conceding the correctness of the Examiner's position, applicants have canceled claims 3, 4, and 92, and added new claims 93 and 94. Applicants note that claim 93 is directed to a specific peptide having a sequence defined in the claim. This peptide differs from both of the human-derived peptides disclosed by Sato et al., one of 153 amino acids (full length CRAF-1) and the other of 181 amino acids (a fragment of CRAF-1), in that the claimed peptide is shorter in length (only 153 residues). Applicants assert, therefore, that claim 93 is not anticipated by Sato et al.

In addition, applicants' claim 94 recites a specific peptide having a sequence defined in the claim. This sequence is included within SEQ ID NO:1. Applicants note that SEQ ID NO:1 describes a peptide derived from a mouse. In contrast, Sato et al. disclose two human-derived peptides, one of 543 amino acids (full length CRAF-1) and the other of 181 amino acids (a fragment of CRAF-1). Applicants note that the specific peptides described in claim 94 contain residue differences with both the fragment and the full-length human sequences disclosed by Sato et al. For example, there is a threonine residue at position 390 in the claimed peptide, whereas both the Sato peptides have a methionine at their corresponding position (residue 366 by Sato's numbering). For example, there is a further difference at residue 373. with the claimed peptide

Applicants: David Baltimore et al.
Serial No.: CPA of 08/813,323
Filed : March 10, 1997
Page 6


having an alanine at that position and both the Sato fragments having a valine (residue 349 by Sato's numbering). Thus, Sato et al. does not anticipate applicant's claimed invention.

In summary, in light of the remarks made hereinabove, applicants respectfully request that the Examiner reconsider and withdraw the various grounds of rejection set forth in the February 12, 2002 Final Office Action.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

No fee, other than the \$55.00 fee for a one-month extension of time is deemed necessary in connection with the filing of this Amendment. If any such fee is required, authorization is hereby given to charge the amount of such fee to Deposit Account No. 03-3125.

Respectfully submitted,




John P. White
Registration No. 28,678
Attorney for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Honorable Commissioner for Patents and Trademarks, Washington, D.C. 20231, BOX AF



John P. White
Reg. No. 28,678

6/12/02
Date



50659.ST25

COPY OF PAPERS
ORIGINALLY FILED

SEQUENCE LISTING

<110> Baltimore, David
Cheng, Genhong
Ye, Zheng-Sheng
Lederman, Seth
Cleary, Aileen

<120> Truncated Craf-1 Inhibits CD40 Signalling

<130> 0575/50659

<140> US/ 08/813,323

<141> 1997-03-10

<160> 5

<170> PatentIn version 3.1

<210> 1

<211> 567

<212> PRT

<213> Mouse Sp.

<400> 1

Met Glu Ser Ser Lys Lys Met Asp Ala Ala Gly Thr Leu Gln Pro Asn
1 5 10 15

Pro Pro Leu Lys Leu Gln Pro Asp Arg Gly Ala Gly Ser Val Leu Val
20 25 30

Pro Glu Gln Gly Gly Tyr Lys Glu Lys Phe Val Lys Thr Val Glu Asp
35 40 45

Lys Tyr Lys Cys Glu Lys Cys Arg Leu Val Leu Cys Asn Pro Lys Gln
50 55 60

Thr Glu Cys Gly His Arg Phe Cys Glu Ser Cys Met Ala Ala Leu Leu
65 70 75 80

Ser Ser Ser Ser Pro Lys Cys Thr Ala Cys Gln Glu Ser Ile Ile Lys
85 90 95

Asp Lys Val Phe Lys Asp Asn Cys Cys Lys Arg Glu Ile Leu Ala Leu
100 105 110

Gln Val Tyr Cys Arg Asn Glu Gly Arg Gly Cys Ala Glu Gln Leu Thr
115 120 125

Leu Gly His Leu Leu Val His Leu Lys Asn Glu Cys Gln Phe Glu Glu
130 135 140

Leu Pro Cys Leu Arg Ala Asp Cys Lys Glu Lys Val Leu Arg Lys Asp
145 150 155 160

Leu Arg Asp His Val Glu Lys Ala Cys Lys Tyr Arg Glu Ala Thr Cys
 165 170 175
 Ser His Cys Lys Ser Gln Val Pro Met Ile Lys Leu Gln Lys His Glu
 180 185 190
 Asp Thr Asp Cys Pro Cys Val Val Val Ser Cys Pro His Lys Cys Ser
 195 200 205
 Val Gln Thr Leu Leu Arg Ser Glu Leu Ser Ala His Leu Ser Glu Cys
 210 215 220
 Val Asn Ala Pro Ser Thr Cys Ser Phe Lys Arg Tyr Gly Cys Val Phe
 225 230 235 240
 Gln Gly Thr Asn Gln Gln Ile Lys Ala His Glu Ala Ser Ser Ala Val
 245 250 255
 Gln His Val Asn Leu Leu Lys Glu Trp Ser Asn Ser Leu Glu Lys Lys
 260 265 270
 Val Ser Leu Leu Gln Asn Glu Ser Val Glu Lys Asn Lys Ser Ile Gln
 275 280 285
 Ser Leu His Asn Gln Ile Cys Ser Phe Glu Ile Glu Ile Glu Arg Gln
 290 295 300
 Lys Glu Met Leu Arg Asn Asn Glu Ser Lys Ile Leu His Leu Gln Arg
 305 310 315 320
 Val Ile Asp Ser Gln Ala Glu Lys Leu Lys Glu Leu Asp Lys Glu Ile
 325 330 335
 Arg Pro Phe Arg Gln Asn Trp Glu Glu Ala Asp Ser Met Lys Ser Ser
 340 345 350
 Val Glu Ser Leu Gln Asn Arg Val Thr Glu Leu Glu Ser Val Asp Lys
 355 360 365
 Ser Ala Gly Gln Ala Ala Arg Asn Thr Gly Leu Leu Glu Ser Gln Leu
 370 375 380
 Ser Arg His Asp Gln Thr Leu Ser Val His Asp Ile Arg Leu Ala Asp
 385 390 395 400
 Met Asp Leu Arg Phe Gln Val Leu Glu Thr Ala Ser Tyr Asn Gly Val
 405 410 415

Leu Ile Trp Lys Ile Arg Asp Tyr Lys Arg Arg Lys Gln Glu Ala Val
420 425 430

Met Gly Lys Thr Leu Ser Leu Tyr Ser Gln Pro Phe Tyr Thr Gly Tyr
435 440 445

Phe Gly Tyr Lys Met Cys Ala Arg Val Tyr Leu Asn Gly Asp Gly Met
450 455 460

Gly Lys Gly Thr His Leu Ser Leu Phe Phe Val Ile Met Arg Gly Glu
465 470 475 480

Tyr Asp Ala Leu Leu Pro Trp Pro Phe Lys Gln Lys Val Thr Leu Met
485 490 495

Leu Met Asp Gln Gly Ser Ser Arg Arg His Leu Gly Asp Ala Phe Lys
500 505 510

Pro Asp Pro Asn Ser Ser Ser Phe Lys Lys Pro Thr Gly Glu Met Asn
515 520 525

Ile Ala Ser Gly Cys Pro Val Phe Val Ala Gln Thr Val Leu Glu Asn
530 535 540

Gly Thr Tyr Ile Lys Asp Asp Thr Ile Phe Ile Lys Val Ile Val Asp
545 550 555 560

Thr Ser Asp Leu Pro Asp Pro
565

<210> 2
<211> 568
<212> PRT
<213> Homo Sapiens

<400> 2

Met Glu Ser Ser Lys Lys Met Asp Ser Pro Gly Ala Leu Gln Thr Asn
1 5 10 15

Pro Pro Leu Lys Leu His Thr Asp Arg Ser Ala Gly Thr Pro Val Phe
20 25 30

Val Pro Glu Gln Gly Gly Tyr Lys Glu Lys Phe Val Lys Thr Val Glu
35 40 45

Asp Lys Tyr Lys Cys Glu Lys Cys His Leu Val Leu Cys Ser Pro Lys
50 55 60

Gln Thr Glu Cys Gly His Arg Phe Cys Glu Ser Cys Met Ala Ala Leu
65 70 75 80

Leu Ser Ser Ser Ser Pro Lys Cys Thr Ala Cys Gln Glu Ser Ile Val
85 90 95

Lys Asp Lys Val Phe Lys Asp Asn Cys Cys Lys Arg Glu Ile Leu Ala
100 105 110

Leu Gln Ile Tyr Cys Arg Asn Glu Ser Arg Gly Cys Ala Glu Gln Leu
115 120 125

Thr Leu Gly His Leu Leu Val His Leu Lys Asn Asp Cys His Phe Glu
130 135 140

Glu Leu Pro Cys Val Arg Pro Asp Cys Lys Glu Lys Val Leu Arg Lys
145 150 155 160

Asp Leu Arg Asp His Val Glu Lys Ala Cys Lys Tyr Arg Glu Ala Thr
165 170 175

Cys Ser His Cys Lys Ser Gln Val Pro Met Ile Ala Leu Gln Lys His
180 185 190

Glu Asp Thr Asp Cys Pro Cys Val Val Val Ser Cys Pro His Lys Cys
195 200 205

Ser Val Gln Thr Leu Leu Arg Ser Glu Leu Ser Ala His Leu Ser Glu
210 215 220

Cys Val Asn Ala Pro Ser Thr Cys Ser Phe Lys Arg Tyr Gly Cys Val
225 230 235 240

Phe Gln Gly Thr Asn Gln Gln Ile Lys Ala His Glu Ala Ser Ser Ala
245 250 255

Val Gln His Val Asn Leu Leu Lys Glu Trp Ser Asn Ser Leu Glu Lys
260 265 270

Lys Val Ser Leu Leu Gln Asn Glu Ser Val Glu Lys Asn Lys Ser Ile
275 280 285

Gln Ser Leu His Asn Gln Ile Cys Ser Phe Glu Ile Glu Ile Glu Arg
290 295 300

Gln Lys Glu Met Leu Arg Asn Asn Glu Ser Lys Ile Leu His Leu Gln
305 310 315 320

Arg Val Ile Asp Ser Gln Ala Glu Lys Leu Lys Glu Leu Asp Lys Glu
325 330 335

Ile Arg Pro Phe Arg Gln Asn Trp Glu Glu Ala Asp Ser Met Lys Ser
340 345 350

Ser Val Glu Ser Leu Gln Asn Arg Val Thr Glu Leu Glu Ser Val Asp
355 360 365

Lys Ser Ala Gly Gln Val Ala Arg Asn Thr Gly Leu Leu Glu Ser Gln
370 375 380

Leu Ser Arg His Asp Gln Met Leu Ser Val His Asp Ile Arg Leu Ala
385 390 395 400

Asp Met Asp Leu Arg Phe Gln Val Leu Glu Thr Ala Ser Tyr Asn Gly
405 410 415

Val Leu Ile Trp Lys Ile Arg Asp Tyr Lys Arg Arg Lys Gln Glu Ala
420 425 430

Val Met Gly Lys Thr Leu Ser Leu Tyr Ser Gln Pro Phe Tyr Thr Gly
435 440 445

Tyr Phe Gly Tyr Lys Met Cys Ala Arg Val Tyr Leu Asn Gly Asp Gly
450 455 460

Met Gly Lys Gly Thr His Leu Ser Leu Phe Phe Val Ile Met Arg Gly
465 470 475 480

Glu Tyr Asp Ala Leu Leu Pro Trp Pro Phe Lys Gln Lys Val Thr Leu
485 490 495

Met Leu Met Asp Gln Gly Ser Ser Arg Arg His Leu Gly Asp Ala Phe
500 505 510

Lys Pro Asp Pro Asn Ser Ser Ser Phe Lys Lys Pro Thr Gly Glu Met
515 520 525

Asn Ile Ala Ser Gly Cys Pro Val Phe Val Ala Gln Thr Val Leu Glu
530 535 540

Asn Gly Thr Tyr Ile Lys Asp Asp Thr Ile Phe Ile Lys Val Ile Val
545 550 555 560

Asp Thr Ser Asp Leu Pro Asp Pro
565

<210> 3
 <211> 2359
 <212> DNA
 <213> Mouse Sp.

<400> 3
 ggcggcggag gatgcgcgcg gcgcctgagc cggccgaacg ggcggcctcg gggtagcagg 60
 tccccattac ttgaaggata aggctggcac ggctccgacg tctgtgtgga agcttctccc 120
 tcccttctga gcttctctag actccttaca gcgcacggca cagaatttca gtttcctaag 180
 atggagtcac gcaaaaagat ggatgctgct ggcacactgc agcctaacc acccctaaag 240
 ctgcagcctg atcgcggcgc agggctcctg ctctgtccgg agcaaggagg ctacaaggag 300
 aagtttgtga agacgggtga agacaagtac aagtgcgaga agtgccgcct ggtgctgtgc 360
 aacccgaagc agaeggagtg tggccaccgg ttctgcgaga gctgcatggc cgcctgctg 420
 agctcctcca gtccaaaatg cacagcgtgc caagaaagca tcatcaaaga caagggtgtt 480
 aaggataatt gctgcaagag agagattctg gcccttcagg tctactgtcg gaatgaaggc 540
 agaggttgtg cggagcagct gactctggga catctgctgg tgcacctaaa aatgaatgt 600
 cagtttgagg aacttcctg tctgcgtgcc gactgcaaag aaaaagtact gagaaaagac 660
 ttgcgggatc acgtggaaaa ggctgtaaa taccgcgagg ccacgtgcag tcaactgcaag 720
 agccaagtgc ccatgatcaa actgcagaaa catgaagaca cagattgtcc ctgtgtggtg 780
 gtatcctgcc ctcaagtg cagcgttcag actcttctaa ggagtgagtt gagtgcacac 840
 ttgtccgagt gtgtcaatgc cccagcacc ttagtattta agcgtatgg ctgcgttttt 900
 cagggtagaa accagcagat caaggcccat gaggccagct ccgcggtaca gcacgtgaac 960
 ctgctgaagg agtggagcaa ctccctggag aagaaggttt ccctgctgca gaatgaaagt 1020
 gttgagaaaa acaagagcat ccaaagcctg cacaaccaga tctgcagctt tgagatcgag 1080
 attgagaggc agaaggagat gctccgaaac aacgagtcca agatccttca cctgcagcgg 1140
 gtaatcgaca gccaagcaga gaaactgaaa gaactggaca aggagatccg tcccttcagg 1200
 cagaactggg aggaagcggg cagcatgaag agcagtgtgg agtccctcca gaacgagtg 1260
 actgagctgg agagcgtaga caaaagtgcg gggcaggcgg ctgcgaacac aggctgctg 1320
 gagtcccagc tgagccggca tgaccagacg ttgagtgttc atgacatccg cttggccgac 1380
 atggacctgc ggttccaggt cctcgagacc gccagctaca acgggggtgct gatctggaag 1440
 atccgtgact acaagcgccg gaagcaggag gccgtcatgg ggaagaccct gtctctctac 1500
 agccagcctt tctacacagg ttattttggc tataagatgt gtgccagggt ctacctgaat 1560
 ggggacggaa tggggaaagg gacacacttg tcgctgtttt ttgtcattat gcgtggagaa 1620
 tatgatgctc tgttgccatg gccgttcaag cagaaagtga cacttatgct gatggatcag 1680
 gggctccttc gccgtcatct gggagatgcg ttcaagcctg accccaacag cagcagcttc 1740

aagaaaccca	ccggagagat	gaatatcgcc	tctggctgcc	cagtctttgt	cgccaaact	1800
gttctagaga	acgggacgta	tattaaagat	gatacaatct	ttattaaggt	catagtggat	1860
acctcggatc	tgcttgaccc	ctgacaagaa	agcagggcgg	tggattcagc	agaaggtaac	1920
tcctctgggg	gggtgagcta	gtgtcttcac	ggaggtcctc	gccctcagaa	aggaccttgt	1980
ggcgcagagg	aagcagccgg	aggaggagaa	ggaggtcgag	tggctggcag	gagagccaca	2040
tgtgaaaaca	gacccaacg	gattttctaa	taaactagcc	acaccactc	tgaaggatta	2100
tttatccatc	aacaagataa	atactgctgt	cagagaaggt	tttcattttc	attttaaaag	2160
atctagtatt	aagggtgggaa	catatatgct	aaaaagaaac	atgatttttc	ttccttaact	2220
taaacaccaa	aaagagaaca	catgtggggg	tagctggagt	gtgtacagta	cctcgagggc	2280
ttaaaatcat	aaacaatcac	atactcatcc	taaaattcag	ggtgcaactc	cgtttcaaat	2340
attgtatat	gtctattta					2359

```
<210> 4
<211> 2455
<212> DNA
<213> Homo Sapiens
```

[illegible]

ctcgctcgaa aagaagttt ccttggtgca gaatgaaagt gtagaaaaaa acaagagcat 1080
 acaaagtttg cacaatcaga tatgtagctt tgaaattgaa attgagagac aaaaggaaat 1140
 gcttcgaaat aatgaatcca aaatccttca tttacagcga gtgatcgaca gccaagcaga 1200
 gaaactgaag gagcttgaca aggagatccg gcccttccgg cagaactggg aggaagcaga 1260
 cagcatgaag agcagcgtgg agtcctcca gaaccgcgtg accgagctgg agagcgtgga 1320
 caagagtgcg gggcaagtgg ctcggaacac aggctgctg gagtcccagc tgagccggca 1380
 tgaccagatg ctgagtgtgc acgacatccg cctagccgac atggacctgc gcttccaggt 1440
 cctggagacc gccagctaca atggagtgtc catctggaag attcgcgact acaagcggcg 1500
 gaagcaggag gccgtcatgg ggaagaccct gtccctttac agccagcctt tctacactgg 1560
 ttactttggt tataagatgt gtgccagggt ctactgaac ggggacggga tggggaaggg 1620
 gacgcacttg tcgctgtttt ttgtcatcat gcgtggagaa tatgatgcc tgcttccttg 1680
 gccgtttaag cagaaagtga cactcatgct gatggatcag gggtcctctc gacgtcattt 1740
 gggagatgca ttcaagcccg accccaacag cagcagcttc aagaagccca ctggagagat 1800
 gaatatcgcc tctggctgcc cagtctttgt ggcccaaact gttctagaaa atgggacata 1860
 tattaagat gatacaattt ttattaaagt catagtggat acctcggatc tgcccgatcc 1920
 ctgataagta gctggggagg tggatttagc agaaggcaac tcctctgggg gatttgaacc 1980
 ggtctgtctt cactgaggtc ctgcgctca gaaaaggacc ttgtgagacg gaggaagcgg 2040
 cagaaggcgg acgcgtgccg gcgggaggag ccacgcgtga gcacacctga cacgttttat 2100
 aatagactag ccacacttca ctctgaagaa ttatttatcc ttcaacaaga taaatattgc 2160
 tgctcagagaa ggttttcatt ttcattttta aagatctagt taattaaggt ggaaaacata 2220
 tatgctaaac aaaagaaaca tgatttttct tccttaaact tgaacaccaa aaaaacacac 2280
 acacacacac acgtggggat agctggacat gtcagcatgt taagtaaaag gagaatttat 2340
 gaaatagtaa tgcaattctg atatcttctt tctaaaattc aagagtgcga ttttgtttca 2400
 aatacagtat attgtctatt ttttaaggcct ccaaaaaaaaa aaaaaattcc ggccg 2455

<210> 5
 <211> 6
 <212> PRT
 <213> Homo Sapiens

<400> 5

Lys Ala Cys Lys Tyr Arg
1 5